Q-omics provides the consensus-scored C20orf141 profile across patient tissues and cancer cell-line models. C20orf141 expression is associated with patient survival in 19 of 34 cancer types, with the highest sampling consensus in KIRC. Among the 18 cancer types available for tumor–normal comparison, C20orf141 is differentially expressed in 8, with the highest sampling consensus in HNSC. Additionally, C20orf141 RNA expression shows 8,922 significant gene co-expression associations, with the highest sampling consensus in BLCA. Together, these results highlight KIRC, HNSC, and BLCA as cancer lineages where C20orf141 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for C20orf141 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes C20orf141 survival associations across molecular data types. C20orf141 RNA expression shows survival associations in the most cancer types (19), followed by mutation status (4). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible C20orf141 RNA expression–survival associations across cancer types. High C20orf141 expression shows unfavorable associations in KIRC, LUAD, SCLC, UVM, COAD and HNSC. The KIRC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify KIRC as the clearest survival context for C20orf141 RNA expression.
This table summarizes C20orf141 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 8. The strongest signals are observed in HNSC for RNA.
This table ranks reproducible tumor–normal expression differences for C20orf141. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. C20orf141 shows higher tumor expression in HNSC, KIRC, LUAD, LUSC, KIRP and COAD. The HNSC box plot shows higher C20orf141 RNA expression in tumor versus normal tissue (log2 FC = +0.734, t-test p < 0.001).
This table shows molecular features associated with C20orf141 in patient tissues and cancer cell lines. In patient samples, C20orf141 shows the broadest associations at the RNA and protein expression levels, with BLCA recurring as the lineage with the largest associated feature set. In cancer cell lines, C20orf141 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in CNS, while CRISPR and shRNA rows add functional-dependency signals in UPPER_AERODIGESTIVE_TRACT and SOFT_TISSUE.
